Raj Patil
Vermögen: 33 650 $ am 31.07.2026
Vermögen: 33 650 $ am 31.07.2026
Raj Patil is currently Chief Scientific Officer at OKYO Pharma Ltd. since 2021.
Former positions include Associate Director-Research at Alcon Laboratories, Inc. from 2004 to 2011, Associate Director-Research at Novartis Institutes for Biomedical Research, Inc. from 2011 to 2013, Assistant Professor at the University of Washington from 1992 to 2001, Associate Professor at the University of Nebraska Medical Center from 2001 to 2004, Vice President-Advanced Ocular Delivery Systems at iVeena Delivery Systems, Inc. from 2013 to 2018, Vice President-Research & Development at Ora, Inc. from 2020 to 2021, and Associate Professor at Duke-NUS Graduate Medical School Singapore from 2011 to 2017.
Education includes a doctorate from National Chemical Laboratory.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OKYO PHARMA LIMITED 0,04 % | 27.07.2026 | 20.030 ( 0,04 % ) | 33 650 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| WEST AFRICAN MINERALS CORP | Technik-/Wissenschafts-/F&E-Leiter | 21.09.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
Ora, Inc.
Ora, Inc. Medical SpecialtiesHealth Technology Develops ophthalmic products and provides clinical research services | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2021 |
iVeena Delivery Systems, Inc.
iVeena Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology Manufactures eye drops | Corporate Officer/Principal | 01.01.2018 |
Duke-NUS Graduate Medical School Singapore
Duke-NUS Graduate Medical School Singapore Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.12.2017 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01.01.2013 |
Alcon Laboratories, Inc.
Alcon Laboratories, Inc. Medical SpecialtiesHealth Technology Operates as an eye care device company | Corporate Officer/Principal | 01.06.2011 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
OKYO Pharma Ltd.
OKYO Pharma Ltd. BiotechnologyHealth Technology Develops next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alcon Laboratories, Inc.
Alcon Laboratories, Inc. Medical SpecialtiesHealth Technology Operates as an eye care device company | Health Technology |
University of Nebraska Medical Center
University of Nebraska Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
National Chemical Laboratory
National Chemical Laboratory Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ora, Inc.
Ora, Inc. Medical SpecialtiesHealth Technology Develops ophthalmic products and provides clinical research services | Health Technology |
Duke-NUS Graduate Medical School Singapore
Duke-NUS Graduate Medical School Singapore Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
iVeena Delivery Systems, Inc.
iVeena Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology Manufactures eye drops | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen